Lexaria Bioscience Corp. (NASDAQ: LEXX) announced on April 29, 2026, that it has extended its Material Transfer Agreement (MTA) with an unnamed pharmaceutical company ("PharmaCO") through December 31, 2026. The original agreement, entered into on August 30, 2024, was designed to evaluate Lexaria's DehydraTECH™ technology in a pre-clinical setting. The extension accommodates the time needed for PharmaCO to receive and review Lexaria's 2026 research and development (R&D) results related to GLP-1 drugs.
The extension allows both parties to continue their relationship under the MTA, keep the temporary exclusive license active, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams. This move underscores the potential of Lexaria's drug delivery platform in the highly competitive GLP-1 sector, which includes drugs for diabetes and weight loss.
Over the past 12 months, Lexaria has advanced its GLP-1 development program, with progress in three key 2026 R&D studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of 2026. These studies are designed to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria's technology.
DehydraTECH is Lexaria's patented drug delivery formulation and processing platform that improves oral drug absorption. It has demonstrated the ability to increase bio-absorption, reduce side effects, and enhance drug delivery across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. More information is available at www.lexariabioscience.com.
The extension of the MTA indicates continued interest from PharmaCO in Lexaria's technology, which could lead to further collaboration or licensing agreements. The GLP-1 market is rapidly growing, and effective oral delivery technologies are in high demand to improve patient compliance and outcomes. Lexaria's DehydraTECH platform may offer a competitive advantage if the upcoming study results are positive.
Forward-looking statements in the press release highlight risks and uncertainties, including regulatory approvals, scientific discovery, and the ability to maintain collaborations. The company disclaims any obligation to update these statements. Investors are directed to the original release on www.newmediawire.com for further details.
